uniQure Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

uniQure N.V. (NASDAQ: QURE) announced the granting of equity awards to 32 newly hired employees as an incentive for their employment. As per Nasdaq Listing Rule 5635(c)(4), the grants, approved on April 29, 2022, include 84,900 restricted stock units and options to purchase 119,000 ordinary shares at an exercise price of $14.94 per share, reflecting the share's closing price on the grant date. The options will vest over four years, while the RSUs will vest over three years, contingent on the employees' continued service.

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, June 22, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the Company granted equity awards to 32 newly hired employees as a material inducement to commencing their employment. The equity grants were approved on April 29, 2022 (the “Grant Date”) in accordance with Nasdaq Listing Rule 5635(c)(4).

In the aggregate, the employees received 84,900 restricted stock units (“RSUs”) and options to purchase 119,000 ordinary shares of uniQure. Each option has an exercise price of $14.94 per share, the closing price per ordinary share as reported by Nasdaq on the Grant Date. Each option has a ten-year term and will vest over four years from the Grant Date, with 25% of the original number of shares vesting on the first anniversary of the Grant Date and an additional 6.25% of the shares vesting in approximately equal quarterly installments over the twelve successive quarters following the first anniversary of the Grant Date. The RSUs will vest over three years, with one-third of the RSUs vesting annually on each successive anniversary of the Grant Date. The vesting of each grant of options and RSUs is subject to the employee’s continued service with the Company through the applicable vesting dates.

About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, Huntington's disease, refractory temporal lobe epilepsy, Fabry disease, and other diseases. www.uniQure.com

uniQure Contacts:

FOR INVESTORS:		FOR MEDIA:
Maria A. Cantor	Chiara Russo	Tom Malone
Direct: 339-970-7536	Direct: 617-306-9137	Direct: 339-970-7558
Mobile: 617-680-9452	Mobile: 617-306-9137	Mobile: 339-223-8541
m.cantor@uniQure.com	c.russo@uniQure.com	t.malone@uniQure.com

FAQ

What equity awards were granted by uniQure on June 22, 2022?

uniQure granted 84,900 restricted stock units and options to purchase 119,000 ordinary shares to 32 newly hired employees.

What is the exercise price for the options granted by uniQure?

The options granted by uniQure have an exercise price of $14.94 per share.

When were the equity awards approved for uniQure employees?

The equity awards were approved on April 29, 2022.

How will the equity awards vest for uniQure employees?

The options will vest over four years with 25% vesting after the first year, while the RSUs will vest over three years with one-third vesting annually.

What is the significance of the Nasdaq Listing Rule 5635(c)(4) in uniQure's equity grants?

The grants were made in accordance with Nasdaq Listing Rule 5635(c)(4), which allows companies to issue equity awards as an inducement for new employees.